UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549





FORM 10-K/A

(AMENDMENT NO. 1)





(Mark One)

|x | ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ------------------------------------------------------------------------------------

For the fiscal year ended December 31, 2015

OR



| ̈ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------------

For the transition period from
                     to

Commission
File Number: 001-36508





KITE PHARMA, INC.

(Exact Name of Registrant as Specified in Its Charter)







|                                                               |  |                                  
|-------------------------------------------------------------- |  | ---------------------------------
|Delaware                                                       |  | 27-1524986                       
|(State or Other Jurisdiction of
Incorporation or Organization) |  | (IRS Employer
Identification No.)
|                                                               | 
|2225 Colorado Avenue
Santa Monica, California                  |  | 90404                            
|(Address of Principal Executive Offices)                       |  | (Zip Code)                       

(310) 824-9999

(Registrants Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:



|                                         |  |                                          
|---------------------------------------- |  | -----------------------------------------
|Title of each class                      |  | Name of each exchange on which
registered
|Common Stock, par value $0.001 per share |  | The NASDAQ Global Select Market          

Securities registered pursuant to Section 12(g) of the Act: None







Indicate by check mark if the registrant is a well-known seasoned
issuer, as defined in Rule 405 of the Securities Act.    YesxNo   ̈

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the
Act.    Yes ̈No  x

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90
days.    YesxNo   ̈

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such
files).    YesxNo   ̈

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not
contained herein, and will not be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form
10-K.    x

Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of
the Exchange Act.



|                        |  |                                                  |  |                           |  |  
|----------------------- |  | ------------------------------------------------ |  | ------------------------- |  | -
|Large accelerated filer |  | x                                                |  | Accelerated filer         |  |  ̈
|                        |  |                                                  | 
|Non-accelerated filer   |  |  ̈  (Do not check if a smaller reporting company) |  | Smaller reporting company |  |  ̈

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Act).    Yes ̈No  x

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based on the closing price of
the registrants common stock as reported on The NASDAQ Global Select Market on June 30, 2015, the last business day of the registrants most recently completed second quarter, was $1,863 million.

As of February 23, 2016, there were 48,839,557 shares of the registrants common stock, par value $0.001 per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrants definitive Proxy Statement relating to its 2016 Annual Meeting of Stockholders were incorporated by
reference into Part III of the Annual Report on Form 10-K that this filing amends. Such Proxy Statement was filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which such Annual Report relates.









---

EXPLANATORY NOTE

This Amendment No. 1 to Form 10-K/A (this Amendment) amends the Annual Report on Form 10-K of Kite Pharma, Inc. (the Company) for
the year ended December 31, 2015, originally filed with the Securities and Exchange Commission on February 29, 2016 (the Original Filing). This Amendment is being filed solely to include revised Exhibits 31.1 and 31.2, which
replace the previously filed versions of those exhibits, to include certain statements required by Item 601(b)(31) of Regulation S-K inadvertently omitted when previously filed.

Except as described as above, no changes have been made to the Original Filing. The Original Filing continues to speak as of the date of the Original Filing,
and the Company has not updated the disclosures contained therein to reflect any events that have occurred as of a date subsequent to the date of the Original Filing. Accordingly, this Amendment should be read in conjunction with the Original
Filing and the Companys filings made with the SEC subsequent to the filing of the Original Filing. The filing of this Amendment is not an admission that the Original Filing, when filed, included any untrue statement of a material fact or
omitted to state a material fact necessary to make a statement not misleading.

PART IV

Item  15. Exhibits, Financial Statement Schedules

The following documents are filed as exhibits to this Amendment:



|               |  |                                                                                                                                               |  |                           |  |               |  |        |  |  |  |  
|-------------- |  | --------------------------------------------------------------------------------------------------------------------------------------------- |  | ------------------------- |  | ------------- |  | ------ |  |  |  | -
|Exhibit
Number |  | Exhibit Description                                                                                                                           |  | Incorporated by Reference |  | FiledHerewith
|               |  | Form                                                                                                                                          |  | SEC File No.              |  | Exhibit       |  | Filing | 
|               |  |                                                                                                                                               |  |                           |  |              
|31.1           |  | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. |  |                           |  |               |  |        |  |  |  | X
|               |  |                                                                                                                                               |  |                           |  |              
|31.2           |  | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. |  |                           |  |               |  |        |  |  |  | X



---

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.



|              |  |  |  |                   |  |                                      
|------------- |  |  |  | ----------------- |  | -------------------------------------
|              |  |  |  | KITE PHARMA, INC.
|              |  |  | 
|June 28, 2016 |  |  |  | By:               |  | /s/ Arie Belldegrun, M.D.            
|              |  |  |  |                   |  | Arie Belldegrun, M.D.                
|              |  |  |  |                   |  | President and Chief Executive Officer



|              |  |  |  |     |  |                        
|------------- |  |  |  | --- |  | -----------------------
|June 28, 2016 |  |  |  | By: |  | /s/ Paul L. Jenkinson  
|              |  |  |  |     |  | Paul L. Jenkinson      
|              |  |  |  |     |  | Chief Financial Officer



---

EXHIBIT INDEX



|               |  |                                                                                                                                               |  |                           |  |               |  |        |  |  |  |  
|-------------- |  | --------------------------------------------------------------------------------------------------------------------------------------------- |  | ------------------------- |  | ------------- |  | ------ |  |  |  | -
|Exhibit
Number |  | Exhibit Description                                                                                                                           |  | Incorporated by Reference |  | FiledHerewith
|               |  | Form                                                                                                                                          |  | SEC File No.              |  | Exhibit       |  | Filing | 
|               |  |                                                                                                                                               |  |                           |  |              
|31.1           |  | Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. |  |                           |  |               |  |        |  |  |  | X
|               |  |                                                                                                                                               |  |                           |  |              
|31.2           |  | Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended. |  |                           |  |               |  |        |  |  |  | X